In IFN-γ-stimulated HNSCC cultures, after treatment with pembrolizumab, we observed a huge heterogeneity in HNSCC, with most (15/23) samples showing reduced IP-10 concentrations and only in 8 of the 23 samples did the IP-10 concentrations increase compared to the IFN-γ-treated control (Figure 1H). The gene discussed is CXCL10; the disease is head and neck squamous cell carcinoma.